The monoclonal Ab neutralizing IGF-1 and IGF-2 named BI836845 is also being tested in a cohort of HR+/HER2– metastatic BC patients, in combination with mTOR and aromatase inhibitors, in a phase 2 clinical trial (NCT02123823). Here, ERBB2 is linked to breast cancer.